Valsartan: a novel angiotensin Type 1 receptor antagonist

Reference

• LEVY D, LARSON MG, VASAN RS, KANNEL WB, HO KKL:The progression from hypertension to congestive heart failure. JAMA (1996) 275:1557–1562.
   PubMed Web of Science ®Google Scholar
• HALL WD, FERRARIO CM, MOORE MA et al: Hyperten-sion-related morbidity and mortality in the Exp. Opin. Pharmacother. (2000) 1(2) southeastern United States. Am. J. Med. Sci. (1997) 313:195–206.
   Google Scholar
• BURT VL, CUTLER JA, HIGGINS M et al.: Trends in theprevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960-1961. Hypertension (1995) 26:60–69.
   PubMed Web of Science ®Google Scholar
• JOINT NATIONAL COMMITTEE ON PREVENTION, DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE: The sixth report of the Joint National Committee on prevention, detection, evalua-tion, and treatment of high blood pressure. Arch. Intern. Med. (1997) 157:2413–2446.
   PubMed Web of Science ®Google Scholar
• ••Treatment guidelines for hypertension.
   Google Scholar
• HEBERT PR, MOSER M, MAYER J, GLYNN RJ, HENNEKENS CH: Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch. Intern. Med. (1993) 153:578–581.
   PubMed Web of Science ®Google Scholar
• THE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. (1987) 316:1429–1435.
   Google Scholar
• PFEFFER MA, BRAUNWALD E, MOYE LA et al: Effect on captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarc-tion. N Engl. J. Merl. (1992) 327:369–377.
   PubMedGoogle Scholar
• SALVETTI A, MATTEI P, SUDANO I: Renal protection and antihypertensive drugs. Current status. Drugs (1999) 57:665–693.
   Google Scholar
• •Review on renal protection and antihypertensive therapy.
   Google Scholar
• STAESSEN JA, FAGARD R, THUS L et al.: Randomiseddouble-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet (1997) 350:757–764.
   PubMed Web of Science ®Google Scholar
• SHEP CO-OPERATIVE RESEARCH GROUP: Prevention ofstroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA (1991) 265:3255–3264.
   Google Scholar
• HANSSON L, ZANCHETTI A, CARRUTHERS SG et al.:Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet (1998) 351:1755–1762.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. Br. Med. J. (1998) 317:703–713.
   PubMed Web of Science ®Google Scholar
• ••Important study on the relevance of optimal blood pressurecontrol in diabetes.
   Google Scholar
• TURNER RR: Role of quality of life in hypertensiontherapy: implication for patient compliance. Cardiology (1992) 80\(Suppl. 1):11–12.
   Google Scholar
• HANSSON L, LINDHOLM LH, NISKANEN L et al.: Effect ofangiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet (1999) 353:611–616.
   PubMed Web of Science ®Google Scholar
• PHILPP T, ANLAUF M, DISTLER A, HOLZGREVE H, MICHAELIS J, WELLEK S: Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. Br. Med. J. (1997) 315:154–159.
   PubMedGoogle Scholar
• SCHMIEDER RE, MARTUS P, KLINGBEIL A: Reversal of left ventricular hypertrophy in essential hypertension: meta-analysis of randomized double-blind studies. JAMA (1996) 275:1507–1513.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl. J. Med. (1992) 327:685–691.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect on enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl. J. Med. (1991) 325:293–302.
   PubMed Web of Science ®Google Scholar
• AIRE STUDY GROUP: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarc-tion with clinical evidence of heart failure. Lancet (1993) 342:821–828.
   PubMed Web of Science ®Google Scholar
• OVERLACK A: ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and manage-ment. Drug Saf (1996) 15:72–80.
   PubMed Web of Science ®Google Scholar
• DE GASPARO M, LEVENS N: Does blockade of ACE inhibitors II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol. Toxicol. (1998) 82:257–271.
   Google Scholar
• URATA H, KINOSHITA A, MISONO KS, BUMPUS FM, HUSAIN A: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. (1990) 265:2348–2357.
   Web of Science ®Google Scholar
• BRINK M, ERNE P, DE GASPARO M et al.: Localization ofthe Angiotensin II receptor subtypes in the human atrium. J. Mol. Cell. Cardiol. (1996) 28:1789–1799.
   Google Scholar
• CRISCIONE L, BRADLEY WA, BeHLMAYER P et al.: Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc. Drug Rev. (1995) 13:230–250.
   Web of Science ®Google Scholar
• CRISCIONE L, DE GASPARO M, BeHLMAYER P, WHITEBREAD S, RAMJOUE HR, WOOD J: Pharmacolog-ical profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II ATi-receptor subtype. Br. J. PharmacoL (1993) 110:761–771.
   PubMed Web of Science ®Google Scholar
• DE GASPARO M, WHITEBREAD S: Binding of valsartan tomammalian angiotensin ATi receptors. Reg. Peptides (1995) 59:303–311.
   PubMed Web of Science ®Google Scholar
• ZIERHUT W, STUDER R, LAURENT D et al. Left ventric- ular wall stress and sarcoplasmatic reticulum Ca2+-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and ATi-receptor blockade. Cardiovasc. Res. (1996) 31:758–768.
   PubMed Web of Science ®Google Scholar
• LEDINGHAM JM, LAVERTY R: Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist. Clin. Exp. Pharmacol. Physiol. (1996) 23:576–578.
   PubMedGoogle Scholar
• KOMETANI M, HAYASHI N, YAMAMOTO S, NAKAO K, INUKAI T: Pharmacological profile of valsartan, a non-peptide angiotensin II Type 1 receptor antago-nist. Arzneim.-Forsch./Drug Res. (1997) 47:613–619.
   PubMed Web of Science ®Google Scholar
• HAYASHI N, FUJIMURA Y, YAMAMOTO S, KOMETANI M, NAKAO K: Pharmacological profile of valsartan, a non-peptide angiotensin II Type 1 receptor antago-nist. 4th communication: improvement of heart failure of rats with myocardial infarction by valsartan. Arzneim.-Forsch./Drug Res. (1997) 47:625–629.
   Google Scholar
• TANIMURA M, SHAROV VG, SHIMOYAMA H et al: Effects of ATi-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure. Am. Physiol. (1999) 276:H1385–H1392.
   Google Scholar
• CLAIR MJ, KROMBACH RS, COKER ML et al: Angiotensin ATi receptor inhibition in pacing induced heart failure: effects on left ventricular myocardial collagen content and composition. J. Mol. Cell. Cardiol. (1998) 30:2355–2364.
   PubMedGoogle Scholar
• WALDMEIER F, FLESCH G, MULLER P et al.:Pharmacokinetics, disposition and biotransformation of [14q-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica (1997) 27:59–71.
   PubMed Web of Science ®Google Scholar
• FLESCH G, MULLER P, LLOYD P: Absolute bioavailabilityand pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur. J. Clin. Pharmacol. (1997) 52:115–120.
   PubMed Web of Science ®Google Scholar
• COLUSSI DM, PARISOT C, ROSSOLINO ML, BRUNNER LA, LEFEVRE GY: Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. J. Clin. Pharmacol. (1997) 37:214–221.
   PubMed Web of Science ®Google Scholar
• MULLER P, FLESCH G, DE GASPARO M, GASPARINI M, HOWALD H: Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur. J. Clin. Pharmacol. (1997) 52:441–449.
   PubMed Web of Science ®Google Scholar
• SIOUFI A, MARFIL F, JAOUEN A et al.: The effect of age on the pharmacokinetics of valsartan. Biopharm. Drug Dispos. (1998) 19:237–244.
   PubMed Web of Science ®Google Scholar
• PRASAD P, SURINDER M, CHOI L et al.: Effect of renal function on the pharmacokinetics of valsartan. Drug Invest. (1997) 13:207–214.
   Google Scholar
• BROOKMAN LJ, ROLAN PE, BENJAMIN IS et al.: Pharmacokinetics of valsartan in patients with liver disease. Clin. Pharmacol. Ther. (1997) 62:272–280.
   PubMed Web of Science ®Google Scholar
• MULLER P, COHEN C, DE GASPARO M, SIOUFI A, RACINE-POON A, HOWALD H: Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur. J. Clin. Pharmacol. (1994) 47:231–245.
   PubMed Web of Science ®Google Scholar
• MAZZOLAI L, MAILLARD M, ROSSAT J, NUSSBERGER J, BRUNNER HR, BURNIER M: Angiotensin II receptor blockade of three ATi receptor antagonist. Hyperten-sion (1999) 33:850–855.
   PubMed Web of Science ®Google Scholar
• MORGAN JM, PALMISANO M, PIRAINO A et al.: The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Clin. Pharmacol Ther. (1997) 61:35–44.
   PubMed Web of Science ®Google Scholar
• CZENDLIK CH, SIOUFI A, PREISWERK G, HOWALD H: Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol. Eur. J. Clin. Pharmacol. (1997) 52:451–459.
   PubMed Web of Science ®Google Scholar
• SCHMIDT EK, ANTONIN KH, FLESCH G, RACINE-POON A:An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur. J. Clin. Pharmacol. (1998) 53:451–458.
   PubMed Web of Science ®Google Scholar
• BINDSCHEDLER M, DEGEN P, FLESCH G, DE GASPARO M,PREISWERK G: Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur. J. Clin. Pharmacol. (1997) 52:371–378.
   PubMed Web of Science ®Google Scholar
• POOL JL, GLAZER R, CHIANG YT, GATLIN M: Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J. Hum. Hypertens. (1999) 13:275–281.
   PubMed Web of Science ®Google Scholar
• OPARIL S, DYKE S; HARRIS F et al.: The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin. Ther. (1996) 18:797–810.
   Google Scholar
• CHRYSANT SG, HOLTZMAN J, LEWIN A et al.: Results of a pilot dose-ranging trial of valsartan in patients with essential hypertension. Am. J. Hypertens. (1996) 9:121A. Abstract G9.
   Google Scholar
• STRODTER D, ZEISSIG I, HEATH R, FEDERLIN K: Angiotensin-II antagonist CGP 48933 (Valsartan)-Ergebnisse einer doppelblinden, plazebo-kontrollierten Multicenter-Studie. Nieren. Hochdruck (1994) 23:217–220.
   Google Scholar
• NEUTEL J, WEBER M, POOL J et al.: Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin. Ther. (1997) 19:447–458.
   PubMed Web of Science ®Google Scholar
• HOLWERDA N, FOGARI R, ANGELI P et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J. Hypertens. (1996) 14:1147–1151.
   PubMed Web of Science ®Google Scholar
• MALLION JM, BOUTELANT S, CHABAUX P et al.: Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press. Monk (1997) 2:179–184.
   PubMedGoogle Scholar
• BLACK HR, GRAFF A, SHUTE D et al.: Valsartan, a newangiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J. Hum. Hypertens. (1997) 11:483–489.
   PubMed Web of Science ®Google Scholar
• COREA L, CARDONI 0, FOGARI R et al: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Gun. Pharmacol Ther. (1996) 60:341–346.
   PubMed Web of Science ®Google Scholar
• HEGNER G, FAUST G, FREYTAG F, MEILENBROCK S, SULLIVAN J, BODIN F: Valsartan, a new angiotensin II antagonist for the treatment of essential hyperten-sion: efficacy and safety compared to hydrochlorothi-azide. Eur. J. Clin. Pharmacol. (1997) 52:173–177.
   PubMed Web of Science ®Google Scholar
• HEDNER T, OPARIL S, RASMUSSEN K et al.: A comparisonof the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am. J. H(1999) 12:414–417.
   Google Scholar
• BREMNER AD, BAUR M, ODDOU-STOCK P, BODIN F: Valsartan: long term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin. Exp. Hypertens. (1997) 19:1263–1285.
   PubMed Web of Science ®Google Scholar
• CIFKOVA R, PELEKA J, HRADEC J et al.: Valsartan and atenolol in patients with severe essential hyperten-sion. J. Hum. Hypertens. (1998) 12:563–567.
   PubMed Web of Science ®Google Scholar
• HALL WD, MONTORO R, LITTLEJOHN T et al.: Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension. Clin. Drug Invest. (1998) 16:203–210.
   PubMed Web of Science ®Google Scholar
• BENZ JR, BLACK HR, GRAFF A, REED A, FITZSIMMONS S, SHI Y: Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J. Hum. Hypertens. (1998) 12:861–866.
   Google Scholar
• THeRMANN PA, KENEDI P, SCHMIDT A, HARDER S, RIETBROCK N: Influence of the angiotensin II antago-nist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation (1998) 98:2037–2042.
   PubMedGoogle Scholar
• TEDESCO MA, RATTI G, AQUINO G et al.: Effects of losartan on hypertension and left ventricular mass: a long-term study. J. Hum. Hypertens. (1998) 12:505–510.
   PubMed Web of Science ®Google Scholar
• KAHAN T, MALMQVIST K, EDNER M, HELD C, OSBAKKEN M: Rate and extent of left ventricular hypertrophy regression: a comparison of angiotensin II blockade with irbesartan and beta-blockade. JACC (1998) 31 (Suppl. C):258C. Abstract 2130.
   Google Scholar
• PLUM J, BeNTEN B, NEMETH R, GRABENSEE B: Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J. Am. Soc. Nephrol. (1998) 9:2223–2234.
   PubMedGoogle Scholar
• FAULHABER HD, MANN JF, STEIN G et al.: Tolerability of valsartan and effects on renal
   Google Scholar
• function in treated hypertensive patients with stablerenal insufficiency. J. Am. Soc. Nephrol. (1997) 8:315A. Abstract A1450.
   Google Scholar
• PERICO N, SPORMANN D, PERUZZI E, BODIN F, SIOUFI A,BERTOCCHI F: Efficacy and tolerability of valsartan compared with lisinopril in patients with hyperten-sion and renal insufficiency. Clin. Drug Invest. (1997) 14:252–259.
   Web of Science ®Google Scholar
• MUIRHEAD N, CHEUNG R, RODGER W et al.: Valsartan (Diovan®): Effect on microalbuminuria in patients with Type II diabetes and nephropathy. JACC (1999) 33(2, Suppl. A):299A. Abstract 872–5.
   Google Scholar
• RUILOPE LM, ALDIGIER JC, PONTICELLI C, ODDOU-STOCK P, BOTTERI F, MANN JF: Safety of the combination of valsartan (V) and benazepril (BZ) in patients with chronic renal disease (CRD). J. Am. Soc. Nephrol. (1997) 8:75A. Abstract A0361.
   Google Scholar
• MAZAYEV VP, FOMINA IG, KAZAKOV EN: Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int. J. Cardiol. (1998) 65:239–246.
   PubMed Web of Science ®Google Scholar
• BARUCH L, ANAND I, COHEN IS, ZIESCHE S, JUDD D, COHN JN: Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator heart failure trial (V-HeFT) study group. Circulation (1999) 99:2658–2664.
   PubMed Web of Science ®Google Scholar
• MICROMEDEX®: Drug evaluations: valsartan. Micromedex, Inc. (1999) 101.
   Google Scholar
• GOSSMANN J, THeRMANN PA, BACHMANN T et al.: Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipi-ents. Kidney Int. (1996) 50:973–978.
   PubMed Web of Science ®Google Scholar
• BENZ J, OSHRAIN C, HENRY D, AVERY C, CHIANG YT, GATLIN M: Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochloro-thiazide. J. Clin. Pharmacol (1997) 37:101–107.
   PubMed Web of Science ®Google Scholar
• FRYE CB, PETTIGREW TJ: Angioedema and photosensi-tive rash induced by valsartan. Pharmacotherapy (1998) 18:866–868.
   PubMed Web of Science ®Google Scholar
• FOGARI R, CORRADI L, POLETTI L, ZOPPI A, MARASI G, MALAMANI GD: Sexual activity in hypertensive males treated with valsartan or carvedilol: a cross-over study. Hypertens. (1999) 17 (Suppl. 3):564. Abstract P1.156.
   Google Scholar
• MANN JF, JULIUS S: The valsartan antihypertensive long-term use evaluation (VALUE) trial of cardiovas-cular events in hypertension. Rationale and design. Blood Press. (1998) 7:176–183.
   PubMedGoogle Scholar
• PITT B, SEGAL R, MARTINEZ FA et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet (1997) 349:747–752.
   PubMed Web of Science ®Google Scholar
• •The first clinical trial on ATI-blockade and mortality in heart failure.
   Google Scholar
• COHN JN, TOGNONI G, GLAZER RD, SPORMANN D, HESTER A: Rationale and design of the valsartan heart failure trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J. Card. Fail. (1999) 5:155–160.
   PubMed Web of Science ®Google Scholar
• POOL J, OPARIL S, HEDNER T, GLAZER R, ODDOU-STOCK P, HESTER A: Dose-response antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin. Ther. (1998) 6:1106–1114.
   Google Scholar